Aquestive Therapeutics (AQST) Set to Announce Earnings on Monday

Aquestive Therapeutics (NASDAQ:AQST) will release its earnings data after the market closes on Monday, November 4th. Analysts expect Aquestive Therapeutics to post earnings of ($0.12) per share for the quarter. Aquestive Therapeutics has set its FY 2024 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.08. The business had revenue of $20.10 million during the quarter, compared to the consensus estimate of $12.62 million. During the same period last year, the firm earned ($0.10) EPS. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aquestive Therapeutics Stock Up 0.2 %

NASDAQ AQST opened at $5.49 on Monday. The company’s 50 day moving average is $4.77 and its 200-day moving average is $3.76. Aquestive Therapeutics has a 12-month low of $1.37 and a 12-month high of $6.23. The firm has a market cap of $499.80 million, a P/E ratio of -13.07 and a beta of 2.85.

Analyst Ratings Changes

Several research firms have recently issued reports on AQST. Leerink Partners boosted their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $8.83.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.